Dr. Brown is an Associate Professor of Molecular Oncology in the Department of Clinical Sciences. He also has faculty appointments in the Epidemiology Section of the Colorado School of Public Health, the Cell and Molecular Biology Graduate Degree Program, and the Department of Ethnic Studies. His research interests include: molecular oncology; epigenetic modifications; innovations in enzyme inhibitor design; innovations in biomanufacturing; cultural and environmental factors of cancer; engaging underrepresented students in the sciences; and engaging undergraduates in research.
PhD, University of Texas at Austin, 2007MS, Georgetown University, , 2002BS, Colorado State University, 1998
Good Clinical Practices
Good Laboratory Practices
Good Manufacturing Practices
BioPharmaceutical Quality Assurance
Jarrell, D.K., Hassell, K.N., Alshiraihi, I., Crans, D.C., and Brown, M.A. Structural Analysis of SMYD3 Lysine Methyltransferase for the Development of Competitive and Specific Enzyme Inhibitors. Diseases, 2022, 10: 1(4). Gordon, J.L., Hinsen, K.J., Reynolds, M.M., Smith, T.A., Tucker, H.O., and Brown, M.A. Anticancer Potential of Nitric Oxide in Neuroblastoma Treatment. Royal Society of Chemistry, Advances, 2021, 11: 9112-9120. Gordon, J.L., Hinsen, K.J., Reynolds, M.M., and Brown, M.A. Anticancer Impact of Nitric Oxide (NO) and NO Combination with SMYD-3 Inhibitor on Breast Carcinomas. Diseases, 2021, 9: 82-98. Brown, M.A., Edwards, M.A., Alshiraihi, I., Geng, H., Dekker, J.D., and Tucker, H.O. The Lysine Methyltransferase SMYD2 is Required for Normal Lymphocyte Development and Survival of Hematopoietic Leukemias. Genes and Immunity, 2020, 21(2): 119-130. Alshiraihi, I.M., Jarrell, D.K., Arhouma, Z., Hassell, K.N., Montgomery, J., Padilla, A., Ibrahim, H.M., Crans, D.C., Kato, T.A., and Brown, M.A. In Silico/In Vitro Hit-to-Lead Methodology Yields SMYD3 Inhibitor that Eliminates Unrestrained Proliferation of Breast Carcinoma Cells. Int. J. Mol. Sci., 2020, 21(24): 9549. Crans, D.C., Brown, M., and Roess D.A. Vanadium Compounds Promote Biocatalysis in Cells through Actions on Cell Membranes. Catalysis Today, 2020, 348: 07.027. Edwards, M.A., Brown, M.A., Alshiraihi, I., Jarrell, D.K., and Tucker, H.O. The Lysine Methyltransferase SMYD2 is Required for Definite Hematopoietic Stem Cell Production in the Mouse Embryo. Vet Sci, 2020, 7(3): 100-106. Gordon, J.L., Reynolds, M.M., and Brown, M.A. Nitric Oxide as a Potential Adjuvant Therapeutic for Neuroblastoma: Effects of NO on Murine N2a Cells. Vet Sci, 2020, 7(2): 51-58. Rhee C., Edwards M., Dang C., Harris J., Brown, M.A., Kim J., and Tucker, H. ARID3A is Required for Mammalian Placenta Development. Developmental Biology. 2017, 422(2) 83-91. Schmidt C., Kim D., Mathur S., Covarrubias D., Das C., Brown M.A., Storsberg J., Tucker H. The Arid3A Transcription Factor Rescues Natural and Ras-V12-induced Senescence via a Rb-dependent Pathway. Amer J Immunol, 2017, 13(4) 216-232. Kim D., Schmidt C., Brown M.A., and Tucker H. Competitive promoter-associated matrix attachment region binding of the Arid3a and Cux1 transcription factors. Diseases, 2017, 5(4) 34-49.
Dr. Brown specializes in molecular oncology and epigenetic factors of embryological development. : Clinical interests: clinical management of colorectal, hepatocellular, and breast carcinomas. : Research interests: molecular oncology; histone modifications; small molecule drug development; epigenetic factors in cardiac morphogenesis and hematopoiesis; cultural and environmental factors of cancer; engaging underrepresented students in the sciences; and engaging undergraduates in research.